Mimpara (Cinacalcet)

Cinacalcet, the active ingredient in Mimpara, is a calcimimetic presented as a 30 mg tablet (also available as 60 mg tablet) for oral use. It treats secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and primary hyperparathyroidism when parathyroidectomy is not indicated.

GNH USA supplies Mimpara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide, providing reliable sourcing for clinical and research use.

Mimpara (cinacalcet) is used to manage disorders of calcium metabolism related to parathyroid hormone dysregulation.

- Secondary hyperparathyroidism (CKD on dialysis): reduces elevated parathyroid hormone levels and helps control serum calcium and phosphorus. - Primary hyperparathyroidism (non‑surgical candidates): lowers PTH secretion when parathyroidectomy is not indicated.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes, often transient. - Diarrhea: loose stools, usually self‑limiting. - Hypocalcemia: low serum calcium levels, may cause tingling. - Muscle cramps: intermittent discomfort. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe hypocalcemia: can lead to seizures or cardiac arrhythmias. - Cardiac arrhythmias: irregular heart rhythms requiring monitoring. - Seizures: rare neurologic events. - Pancreatitis: inflammation of the pancreas, presenting with abdominal pain. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

Before initiating therapy, consider the following precautions: - Monitor serum calcium: regular testing to avoid hypocalcemia. - Adjust dose in renal impairment: reduced clearance may require lower doses. - Cardiac caution: use carefully in patients with known arrhythmias. - Hypersensitivity: discontinue if allergic reactions occur. - Review concomitant calcium‑affecting drugs: assess risk of additive effects. - Store at below 25°C: keep in the original pack, protect from moisture.

Cinacalcet may interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase cinacalcet plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - High‑dose calcium supplements: can blunt the drug’s calcium‑lowering action.

Moderate Interactions (Monitor Closely): - Vitamin D analogs (e.g., calcitriol): combined use may heighten hypocalcemia risk. - Loop diuretics: may affect calcium balance, requiring closer monitoring. - Warfarin: may necessitate INR checks due to potential interaction.